

Supplementary Table S1. Prescription pattern of apixaban, dabigatran and rivaroxaban across centres.

number of centre	type of centre	all n=2971	Apixaban n=953	Dabigatran n=819	Rivaroxaban n=1199
1	academic	709	267 (37.7)	221 (31.2)	221 (31.2)
2	academic	284	101 (35.6)	68 (23.9)	115 (40.5)
3	academic	151	51 (33.8)	37 (24.5)	63 (41.7)
4	regional	272	119 (43.8)	82 (30.1)	71 (26.1)
5	academic	351	65 (18.5)	97 (27.6)	189 (53.8)
6	academic	60	15 (25.0)	7 (11.7)	38 (63.3)
7	military	430	132 (30.7)	73 (17.0)	225 (52.3)
8	regional	248	72 (29.0)	76 (30.6)	100 (40.4)
9	academic	257	93 (36.2)	91 (35.4)	73 (28.4)
10	academic	209	38 (18.2)	67 (32.0)	104 (49.8)

Supplementary Table S2. Factors associated with the selection of individual NOAC over another NOAC for stroke prevention in patients with AF - univariable logistic regression models.

Factors	Apixaban			Dabigatran			Rivaroxaban		
	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p
CHA ₂ DS ₂ -VASc score	1.14	1.09-1.19	< 0.0001	0.94	0.9-0.99	0.0114	0.93	0.9-0.97	0.0008
HAS-BLED score	1.42	1.3-1.55	< 0.0001	0.93	0.85-1.02	0.1114	0.77	0.71-0.84	< 0.0001
Age (per 5 years)	1.19	1.14-1.23	< 0.0001	0.92	0.89-0.95	< 0.0001	0.93	0.9-0.96	< 0.0001
Heart failure	1.37	1.16-1.61	0.0002	0.82	0.69-0.97	0.0187	0.89	0.77-1.04	0.1493
Vascular disease	1.21	1.03-1.41	0.018	1.03	0.88-1.22	0.6852	0.82	0.71-0.95	0.0088
Female	1.28	1.1-1.5	0.0018	0.73	0.62-0.86	0.0001	1.04	0.9-1.2	0.6158
Non-permanent AF	0.65	0.54-0.77	< 0.0001	1.13	0.93-1.37	0.2112	1.37	1.15-1.63	0.0005
Malignancy	1.48	1.04-2.11	0.0282	0.77	0.51-1.17	0.2216	0.84	0.58-1.2	0.3256
Any previous bleeding	2.59	1.86-3.62	< 0.0001	0.81	0.55-1.2	0.2965	0.41	0.28-0.61	< 0.0001
GFR < 60 ml/min/1.73m ²	1.95	1.66-2.28	< 0.0001	0.69	0.59-0.81	< 0.0001	0.75	0.65-0.87	0.0001
Antiplatelets with NOAC	2.37	1.58-3.55	< 0.0001	0.62	0.38-1.04	0.0678	0.58	0.37-0.91	0.0168

Abbreviation: CI, confidence interval; eGFR, estimated glomerular filtration rate; NOAC, non-vitamin K antagonist oral anticoagulant; OR, odds ratio.